Abstracts tagged "Ankylosing spondylitis (AS) and magnetic resonance imaging (MRI)"

Abstract Number: 2709 • 2016 ACR/ARHP Annual Meeting
Which Cells Correspond to the Typical Signals for Fatty and Inflammatory Lesions Seen in Magnetic Resonance Imaging in Ankylosing Spondylitis ? -a Prospective Study Using Biopsy Material Obtained during Spinal Surgery-
Xenofon Baraliakos¹, Heinrich Boehm², Ahmend Samir², Georg Schett³ and Jürgen Braun⁴, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Clinic for spinal surgery, Bad Berka, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: The occurrence of bone marrow edema (BME) and fat metaplasia detected by magnetic resonance imaging (MRI) were shown to be significantly associated with syndesmophyte…
Abstract Number: 1719 • 2015 ACR/ARHP Annual Meeting
Can Structural Progression on MRI of Sacroiliac Joints in Patients with Spondyloarthritis be Reliably Detected and What Type of Calibration Is Necessary to Achieve This?
Walter Maksymowych¹, Susanne Juhl Pedersen², Victoria Navarro-Compán³, Stephanie Wichuk¹, Josefina Marin⁴, Manouk de Hooge⁵, Robert G Lambert⁶, Désirée van der Heijde⁵ and Rosaline van den Berg⁵, ¹Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark, ³Rheumatology, University Hospital La Paz, Madrid, Spain, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Radiology, Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: There is growing interest in the management of early axial spondyloarthritis and intervention with disease-modifying agents while disease is still confined to the sacroiliac…
Abstract Number: 574 • 2012 ACR/ARHP Annual Meeting
Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis
Xenofon Baraliakos¹, Jürgen Braun², D. D. Laurent³, Dominique L. Baeten⁴, D. van der Heijde⁵, Joachim Sieper⁶, Paul Emery⁷, Iain B. McInnes⁸, Jacob M. van Laar⁹, R. Landewe¹⁰, Paul Wordsworth¹¹, Jurgen Wollenhaupt¹², Herbert Kellner¹³, Andrew Wright³, Francois Vandenhende¹⁴, Kath Radford¹⁵, Babul Borah¹⁵ and Hueber Wolfgang¹⁵, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Charitè Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁷Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁸Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁹Newcastle University, Newcastle upon Tyne, United Kingdom, ¹⁰Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹¹Nuffield Orthopaedic Centre, Oxford, United Kingdom, ¹²Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹³Centre for Inflammatory Joint Diseases, Munich, Germany, Munich, Germany, ¹⁴Clinbay, Genappe, Belgium, Genappe, Belgium, ¹⁵Novartis Institutes for BioMedical Research, Basel, Switzerland
Background/Purpose: In a recent proof-of-concept (PoC) trial it was shown that secukinumab, a fully human IgG1k anti-IL17A monoclonal antibody, significantly improved clinical signs and symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].